Human IgG4抗体—艾普蒂 新品

+ +

•  

   

     Microtiter wells were coated with human immunoglobulins with various isotypes. P16103 was used as primary antibody and peroxidase conjugated goat anti-mouse IgG was used as the secondary antibody. Result: P16103 does not cross-react with human IgG1, IgG2, IgG3, IgA, IgM and IgE.    

  
  

•  

   

     Lane 1: 100 ng of human IgG1 ;  Lane 2: 100 ng of human IgG2;  Lane 3: 100 ng of human IgG3;Lane 4: 100 ng of human IgG4;  Lane 5: 100 ng of human IgA ;  Lane 6: 100 ng of human IgM ;  Lane 7: 100 ng of human IgE ;  Result: P16103 can specifically detect human IgG4 by Western blotting;    

  
  

•  

   

     IHC-P analysis of human tonsil tissue by anti-human IgG4 antibody (P16103) IHC-P was performed using sections of the formalin-fixed paraffin-embedded human tonsil tissue;Result: Squamous epithelial cells and non-germinal center cells are positively stained at cytoplasm.    

  
  

Human IgG4 is one of the four subclasses of immunoglobulin G (IgG) in humans, characterized by unique structural and functional properties. It constitutes approximately 3-6% of total serum IgG in healthy individuals. Unlike other IgG subclasses, IgG4 exhibits dynamic flexibility due to its "hinge region," enabling Fab-arm exchange—a process where half-molecules (one heavy-light chain pair) swap with those from other IgG4 antibodies. This results in bispecific, monovalent antibodies that cannot form large immune complexes, contributing to its anti-inflammatory role.

IgG4 is associated with prolonged antigen exposure, often elevated in chronic infections, allergies, or autoimmune conditions. While it weakly activates complement and binds Fc receptors compared to IgG1/IgG3. its limited effector functions help dampen inflammatory responses. However, IgG4 also plays dual roles in diseases: it may block pathogenic antibodies in myasthenia gravis but promote immune evasion in cancers by interfering with IgG1-mediated cytotoxicity.

Therapeutically, IgG4-derived monoclonal antibodies (e.g., pembrolizumab) are widely used in oncology and immunotherapy. However, their intrinsic instability (due to Fab-arm exchange) and shorter serum half-life than IgG1 necessitate engineering (e.g., point mutations) to improve clinical efficacy. Ongoing research aims to unravel its paradoxical roles in immune tolerance and pathology.